ADAPTATION OF CAPSCAN TECHNOLOGY TO HEMATOPOIETIC ASSAYS

描述(取自申请者的摘要)：髋关节 癌症研究公司开发了专利技术 (CapScanTM)用于定量微毛细管内的颗粒， 包括肿瘤细胞集落。Hipple还开创了基于微毛细管的 造血试验用于人类骨髓毒性试验的调查性研究 探员们。自动菌落计数将有助于更快和更少 昂贵的骨髓毒性评估，与现代疗效同步 筛选(即，体外癌细胞系面板)，以便新的 具有良好治疗指数的抗癌和抗艾滋病毒药物， 而不是疗效，将被选为发展的对象。在……里面 第一阶段我们将确定采用CapScanTM的可行性 人类群体的自动定量技术 造血祖细胞(CFU-CM和BFU-E)。在第二阶段，我们会 开发所需的软件和硬件适配 阶段性研究，并将自动化扩展到小鼠造血 集落和需要特殊染色的造血细胞集落 用于检测(CFU-MEG)。如果成功，这将标志着第一个 为造血细胞自动计数开发的技术 每年有10,000多种化合物在抗癌方面进行筛选 药物发现计划，很明显有无数 该技术的商业应用机会。

DESCRIPTION (Obtained from the applicant's abstract): The Hipple Cancer Research Corporation developed patented technology (CapScanTM) for quantitating particles inside microcapillary tubes, includingtumor cell colonies. Hipple also pioneered microcapillary-based hematopoietic assays for human myelotoxicity testing of investigational agents. Automated colony counting would facilitate faster and less expensive myelotoxicity evaluations, keeping pace with modern efficacy screens, (i.e., in vitro cancer cell lines panels), so that new anti-cancer and anti-HIV agents with favorable therapeutic indices, rather than efficacies, would be selected for development. In Phase I we will determine the feasibility of adapting CapScanTM technologies to automated quantitation of colonies of human hematopoietic progenitors (CFU-CM and BFU-E). In Phase II, we will develop the required software and hardware adaptations indicated by the PhaseI research, and extend the automationto murine hematopoietic colonies and to hematopoietic colonies that requirespecial stains fordetection (CFU-Meg). Ifsuccessful, this would mark the first technology developed for automated counting of hematopoietic colonies.With over 10,000 compounds screened each year in anti-cancer drug discoveryprograms, it is obvious that there are numerous opportunities for commercial application of the technology.